Cyclo‐oxygenase‐2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?

[1]  E. Ongini,et al.  Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. , 2011, Gastroenterology.

[2]  S. Hernández-Díaz,et al.  Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases , 2011, Gut.

[3]  S. Hernández-Díaz,et al.  Risk of Upper Gastrointestinal Bleeding With Low-Dose Acetylsalicylic Acid Alone and in Combination With Clopidogrel and Other Medications , 2011, Circulation.

[4]  F. Chan,et al.  Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial , 2010, The Lancet.

[5]  E. Kuipers,et al.  Time‐trends in gastroprotection with nonsteroidal anti‐inflammatory drugs (NSAIDs) , 2010, Alimentary pharmacology & therapeutics.

[6]  P. Tugwell,et al.  Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors , 2009, Drug, healthcare and patient safety.

[7]  F. Chang,et al.  Dexamethasone Inhibits Tumor Necrosis Factor‐α‐stimulated Gastric Epithelial Cell Migration , 2009, Journal of the Chinese Medical Association : JCMA.

[8]  F. Chan,et al.  Guidelines for Prevention of NSAID-Related Ulcer Complications , 2009, The American Journal of Gastroenterology.

[9]  E. Kuipers,et al.  Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. , 2009, Current medical research and opinion.

[10]  C. Cannon,et al.  Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. , 2008, Gastroenterology.

[11]  M. McAlindon,et al.  Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  G. Trifirò,et al.  Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. , 2008, Arthritis and rheumatism.

[13]  C. Metge,et al.  The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. , 2008, Gastroenterology.

[14]  B. Hunt,et al.  Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  A. Seigal,et al.  Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  E. Kuipers,et al.  Adherence to gastroprotection and the risk of NSAID‐related upper gastrointestinal ulcers and haemorrhage , 2007, Alimentary pharmacology & therapeutics.

[17]  A. Barkun,et al.  Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? , 2007, Arthritis and rheumatism.

[18]  G. Eisen,et al.  Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy , 2007, Alimentary pharmacology & therapeutics.

[19]  Á. Lanas,et al.  Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations , 2006, Gut.

[20]  S. Walton,et al.  Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  K. Chu,et al.  Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. , 2005, The American journal of medicine.

[22]  V. Wong,et al.  Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. , 2004, Gastroenterology.

[23]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.

[24]  L. Laine,et al.  Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. , 2004, Gastroenterology.

[25]  M. Numans,et al.  [Guideline 'NSAID use and the prevention of gastric damage']. , 2004, Nederlands tijdschrift voor geneeskunde.

[26]  W. H. So,et al.  Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. , 2004, European journal of pharmacology.

[27]  N. Maskrey,et al.  NSAIDs, gastroprotection and cyclo‐oxygenase‐II‐selective inhibitors * , 2003, Alimentary pharmacology & therapeutics.

[28]  T. Schnitzer,et al.  Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. , 2003, Gastroenterology.

[29]  V. Wong,et al.  Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. , 2002, The New England journal of medicine.

[30]  S. Hernández-Díaz,et al.  Steroids and risk of upper gastrointestinal complications. , 2001, American journal of epidemiology.

[31]  R. Hubbard,et al.  Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis , 2001, American Journal of Gastroenterology.

[32]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[33]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[34]  S. Hernández-Díaz,et al.  Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. , 2000, Archives of internal medicine.

[35]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[36]  D. Graham,et al.  Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. , 1999, JAMA.

[37]  R. Fisher,et al.  Effect of gastric acid suppressants on human gastric motility , 1998, Gut.

[38]  D. Raiford,et al.  Individual Nonsteroidal Antiinflammatory Drugs and Other Risk Factors for Upper Gastrointestinal Bleeding and Perforation , 1997, Epidemiology.

[39]  A. Blum,et al.  Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. , 1996, Gut.

[40]  A. Blum,et al.  Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. , 1994, Gut.

[41]  H. Lamberts,et al.  International primary care classifications: the effect of fifteen years of evolution. , 1992, Family practice.

[42]  W A Ray,et al.  Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. , 1991, Annals of internal medicine.

[43]  B. Macmahon,et al.  Epidemiology: Principles and Methods , 1970 .